{"nctId":"NCT00640562","briefTitle":"Quetiapine Extended Release Depression Symptoms","startDateStruct":{"date":"2008-02"},"conditions":["Schizophrenia","Depression"],"count":216,"armGroups":[{"label":"Quetiapine Extended Release","type":"EXPERIMENTAL","interventionNames":["Drug: Quetiapine Extended Release"]},{"label":"Risperidone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Risperidone"]}],"interventions":[{"name":"Quetiapine Extended Release","otherNames":["Seroquel XR™"]},{"name":"Risperidone","otherNames":["Risperdal"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of written informed consent\n* Patients who satisfy the criteria for diagnosis of schizophrenia or schizoaffective disorder according to DSM-IVTR\n* Baseline depressive symptoms, assessed by means of HAM-D (21-item) score ≥20, and HAM-D item 1 score ≥2\n\nExclusion Criteria:\n\n* Any DSM-IV Axis I disorder other than schizophrenia and schizoaffective disorder\n* Patients treated with depot antipsychotic medications within 1 dosing interval before day 0; patients treated with other AP oral medications during the trial except for the switch period\n* Use of Clozapine within 28 days prior to enrollment or Clozapine non responders\n* Any significant clinical disorder that, in the opinion of the investigator, made the subject unsuitable to be given treatment with an investigational drug\n* An absolute neutrophil count (ANC) of ≤1.5 x 109 per liter\n* Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 12 of Calgary Depression Scale for Schizophrenia (CDSS) Score.","description":"The CDSS scale is used to assess the level of depression in schizophrenia and to estimate the severity of depressive symptoms.\n\nCDSS has 9 items rated on four-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. Anchor point descriptions are provided to aid differentiation between each item score. The first eight items are rated on basis of patients' responses to questions; the 9 item is based on clinician's assessment.\n\nThe sum score is derived by adding the point score of all items (from 0 to 27 points); total score 4-5 is considered for minor depression and 6-7 score for major depression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.31","spread":"6.1"},{"groupId":"OG001","value":"5.53","spread":"6.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 of HAM-D Score","description":"21-item scale for depression. Symptoms are rated finely (on a 5-point scale: absent; doubtful or trivial; mild: moderate severe) or coarsely (on a 3- point scale: absent; doubtful or mild; obvious, distinct, or severe).Total score range 0- 66, higher values represent worse outcome.Number of participants refers to valid for efficacy per protocol. Change:total score at week 12 minus total score at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.83","spread":"10.13"},{"groupId":"OG001","value":"-23.02","spread":"10.33"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 of PANSS Score","description":"30-item scale where each symptom is rated on a severity ranging from 1-7. Symptoms are categorized into 7 items referring to positive, 7 items referring to negative and 16 general psychotic. Total score range 30- 210, higher values represent worse outcome. Number of participants analyzed refers to valid for efficacy per protocol population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102.26","spread":"24.14"},{"groupId":"OG001","value":"100.51","spread":"25.65"}]}]}]},{"type":"SECONDARY","title":"- Change From Baseline to Week 12 of Clinical Global Impression (CGI- Severity of Illness) Score","description":"The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates \"normal, not at all ill\", while a score of 7 indicates \"among the most extremely ill of patients\". The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":"1.33"},{"groupId":"OG001","value":"-1.04","spread":"1.31"}]}]}]},{"type":"SECONDARY","title":"CGI- Global Improvement Mean Score at Week 12","description":"The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates \"normal, not at all ill\", while a score of 7 indicates \"among the most extremely ill of patients\". The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":"4.47"},{"groupId":"OG001","value":"88","spread":"4.55"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 of Drug Attitude Inventory 10 Item Scale (DAI 10) Score","description":"These items are presented as self-report statements with which the patient agrees or disagrees. Each response is scored as +1 if correct or -1 if incorrect. The final score is the grand total of the positive and negative points. A positive score means a positive subjective response. A negative total score means a negative subjective response","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.38","spread":"4.12"},{"groupId":"OG001","value":"76.64","spread":"4.70"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Simpson Angus Scale (SAS) Total Score to Week 12 as an Indication of Neurological Side Effects Section","description":"Extrapyramidal Side Effects (EPS) will be assessed using the Simpson-Angus Scale (SAS; Simpson GN et al 1970) . The CRF is source data for these assessments and day 0 is considered as baseline.\n\nThe SAS scale, containing 10 items, will be rated on a five-point scale where 0 is normal and 4 are severe symptoms. Min score =0, max score 40\n\nChange from start of treatment (day 0) will be calculated as the visit score minus the score at start of treatment for each of the neurological assessments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.74","spread":"5.29"},{"groupId":"OG001","value":"3.88","spread":"5.24"}]}]}]},{"type":"SECONDARY","title":"Concomitant Use of Antidepressive Drugs From Baseline to Week 12","description":"Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to safety population, that is to overall participants excluding 6 participants who did not assume any study drug administration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Screening Visit to Week 12 of Prolactin Live","description":"Plasma prolactin live was drawn prior to morning meal at the screening visit at the last visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.20","spread":"29.77"},{"groupId":"OG001","value":"90.80","spread":"55.78"}]}]}]},{"type":"SECONDARY","title":"Body Mass Index (BMI) at Week 12","description":"Patient weight and height have been be collected in order to assess the Body Mass Index (BMI). The mean BMI values reported are assessed after 12 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.07","spread":"6.65"},{"groupId":"OG001","value":"28.80","spread":"5.31"}]}]}]},{"type":"SECONDARY","title":"Concomitant Use of Antidepressive Drugs From Baseline to Week 12","description":"Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to ITT/safety population, that is to overall participants excluding the 6 participants who did not assume any study drug administration","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":109},"commonTop":["Hyperprolactinemia","Asthenia","Somnolence","Sedation","Hypotension"]}}}